Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Vibrato Aspiration System - Simple, Intuitive Approach to Clot Removal in Acute Pulmonary Embolism - a Safety & Feasibility Study

23. august 2026 oppdatert av: Vicora, Inc.
The study is a prospective, single-arm, multicenter study to evaluate the safety and effectiveness of the Vibrato™ Aspiration System for aspiration mechanical thrombectomy in the treatment of acute PE. This is the First in Man clinical study.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Detaljert beskrivelse

The study objective is to evaluate the safety and effectiveness of the Vibrato™ Aspiration System Aspiration System (hereafter referred to as Vibrato™ Aspiration System) for aspiration mechanical thrombectomy in the treatment of acute PE.

The Vibrato™ Aspiration System is a vibration-assisted aspiration thrombectomy device including attributes designed to improve trackability, maintain a low-profile configuration, and operate without capital equipment. In addition, the Vibrato™ Aspiration System features a novel vibrating distal tip designed to enhance thrombus removal during aspiration while minimizing vascular injury. The vibrating mechanism may reduce procedure times, improve clot removal efficiency, and decrease the need for adjunctive interventions.

Studietype

Intervensjonell

Registrering (Antatt)

10

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Polen, 61-848
        • Har ikke rekruttert ennå
        • Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Uniwersytecki Szpital Kliniczny
        • Hovedetterforsker:
          • Aleksander Araszkiewicz, Professor, MD, PhD
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Polen, 31-202
        • Rekruttering
        • Krakowski Szpital Specjalistyczny im. św. Jana Pawła II
        • Hovedetterforsker:
          • Grzegorz Kopeć, Professor, MD, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

Subjects must meet all following general inclusion criteria:

  1. Age ≥ 18 and ≤ 75 years.
  2. Clinical signs, symptoms, and presentation consistent with acute PE;
  3. PE symptom duration ≤ 14 days;
  4. CTA evidence (site determined) of proximal PE (filling defect in at least one main or interlobar pulmonary artery)
  5. RV/LV ratio of ≥ 0.9 on CTA as assessed by investigator (site determined).
  6. Systolic blood pressure ≥ 90 mmHg;
  7. Stable heart rate < 130 BPM prior to procedure;
  8. Patient is deemed medically eligible for interventional procedure(s), per institutional guidelines and clinical judgment
  9. Informed Consent Form signed
  10. Subject is willing and able to comply with all Clinical Investigation Plan required follow-up visit

Exclusion Criteria:

Subjects must not meet any of the following general exclusion criteria:

  1. Thrombolytic use within 30 days of baseline CT angiogram
  2. Pulmonary hypertension with peak pulmonary artery pressure > 70 mmHg by right heart catheterization (site determined)
  3. Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg;
  4. FiO2 requirement > 40% or > 6 LPM to keep oxygen saturation > 90%;
  5. Hematocrit < 28%;
  6. Platelets < 100,000/ML;
  7. Serum creatinine > 1.8 mg/dL;
  8. International normalized ratio (INR) > 3;
  9. Major trauma injury severity score (ISS) > 15 within the past 14 days
  10. Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months, Pacemaker or Implantable Cardioverter Defibrillators;
  11. Cardiovascular or pulmonary surgery within last 7 days;
  12. Actively progressing cancer requiring chemotherapy
  13. Known bleeding diathesis or coagulation disorder;
  14. Left bundle branch block;
  15. History of severe or chronic pulmonary arterial hypertension;
  16. History of chronic left heart disease with left ventricular ejection fraction ≤ 30%;
  17. History of uncompensated heart failure;
  18. History of underlying lung disease that is oxygen dependent;
  19. History of chest irradiation;
  20. History of heparin-induced thrombocytopenia (HIT);
  21. Patients who are under intubation
  22. Any contraindication to systemic or therapeutic doses of heparin or anticoagulants;
  23. Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated;
  24. Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention;
  25. Life expectancy of < 90 days, as determined by Investigator;
  26. Female who is pregnant or nursing;
  27. Current participation in another investigational drug or device treatment study
  28. History of Hemorrhagic or Ischemic Stroke, including Transient Ischemic Attack, within last 90 days
  29. Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Enhetens gjennomførbarhet
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Single arm study
Vibrato™ Aspiration System for aspiration mechanical thrombectomy in the treatment of acute pulmonary embolism.
Mechanical Thrombectomy for the treatment of Acute Pulmonary Embolism

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety Endpoint: Major Adverse Events
Tidsramme: 48 hours

Major Adverse Events, a composite of:

  • Device-related death within 48 hours
  • Major bleeding within 48 hours
  • Device-related AEs within 48 hours, including:
  • Clinical deterioration
  • Pulmonary vascular injury
  • Cardiac injury
48 hours
Efficacy Endpoint: Reduction in RV/LV Ratio
Tidsramme: 48 hours
Reduction in RV/LV ratio from baseline to 48 hours or discharge by CT angiography
48 hours

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety Endpoint: Device-Related Death
Tidsramme: 48 hours
Device-related death within 48 hours
48 hours
Safety Endpoint: Major Bleeding
Tidsramme: 48 Hours
Major bleeding within 48 hours
48 Hours
Safety Endpoint: Device-Related Clinical Deterioration
Tidsramme: 48 Hours
Device-related clinical deterioration within 48 hours
48 Hours
Safety Endpoint: Device-Related Pulmonary Vascular Injury
Tidsramme: 48 Hours
Device-related pulmonary vascular injury within 48 hours
48 Hours
Safety Endpoint: Cardiac Injury
Tidsramme: 48 Hours
Cardiac injury within 48 hours
48 Hours
Safety Endpoint: Any-Cause Mortality
Tidsramme: 30 Days
Any-cause mortality within 30 days
30 Days
Safety Endpoint: Device-Related Serious Adverse Event
Tidsramme: 30 Days
Device-related Serious Adverse Events (SAEs) within 30 days
30 Days
Safety Endpoint: Symptomatic Recurrence of Pulmonary Embolism
Tidsramme: 30 Days
Symptomatic recurrence of Pulmonary Embolism (PE) within 30 days
30 Days
Efficacy Endpoint: Modified Miller Index Score
Tidsramme: 48 Hours
Change in modified Miller Index Score (MMIS) between baseline and 48 hours post-procedure as assessed by CTA
48 Hours
Efficacy Endpoint: Change in Mean Pulmonary Artery Pressure
Tidsramme: Procedure
Change in mean pulmonary artery pressure measured invasively in the central pulmonary arteries before vs. after the endovascular procedure [measured in mmHg]
Procedure
Efficacy Endpoint: Procedural Change in Cardiac Index
Tidsramme: Procedure
Procedural change in cardiac index [measured in L/min/m^2]
Procedure
Efficacy Endpoint: Length of ICU Stay, Associated with Index Procedure
Tidsramme: 30 Days
Length of stay in the ICU associated with the index procedure [measured in days]
30 Days
Efficacy Endpoint: Length of Total Hospital Stay
Tidsramme: 30 Days
Length of total hospital stay [measured in days]
30 Days
Efficacy Endpoint: Post-Index Procedure Hospital Length of Stay
Tidsramme: 30 Days
Post-index-procedure hospital length of stay [measured in days]
30 Days
Efficacy Endpoint: Procedural Reduction in Pulmonary Artery Mean Pressure
Tidsramme: Procedure
Procedural reduction in pulmonary artery mean pressure [measured in mmHg]
Procedure
Efficacy Endpoint: Procedural Reduction in Pulmonary Artery Systolic Pressure
Tidsramme: Procedure
Procedural reduction in pulmonary artery systolic pressure [measured in mmHg]
Procedure
Efficacy Endpoint: Reduction in Total Pulmonary Vascular Resistance
Tidsramme: Procedure
Procedural reduction in total pulmonary vascular resistance [measured in mmHg ⋅ min/L]
Procedure
Efficacy Endpoint: Change from Baseline in Dyspnea Severity by mMRC Score
Tidsramme: 48 Hours
Change from baseline in Dyspnea severity by mMRC score at the 48-hour visit
48 Hours
Efficacy Endpoint: Change from Baseline in Dyspnea Severity by mMRC Score
Tidsramme: 30 Days
Change from baseline in Dyspnea severity by mMRC score [Time Frame: at the 30 days visit]
30 Days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

21. august 2026

Primær fullføring (Antatt)

1. oktober 2026

Studiet fullført (Antatt)

1. desember 2026

Datoer for studieregistrering

Først innsendt

18. juni 2026

Først innsendt som oppfylte QC-kriteriene

1. juli 2026

Først lagt ut (Faktiske)

6. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

25. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

23. august 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere